Metastatic disease to the liver: Locoregional therapy strategies and outcomes.

Autor:	Zane KE; Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, United States., Cloyd JM; Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH 43210, United States., Mumtaz KS; Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210, United States., Wadhwa V; Department of Radiology, Weill Cornell Medical Center, New York City, NY 10065, United States., Makary MS; Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, United States. mina.makary@osumc.edu.
Jazyk:	angličtina
Zdroj:	World journal of clinical oncology [World J Clin Oncol] 2021 Sep 24; Vol. 12 (9), pp. 725-745.
DOI:	10.5306/wjco.v12.i9.725
Abstrakt:	Secondary cancers of the liver are more than twenty times more common than primary tumors and are incurable in most cases. While surgical resection and systemic chemotherapy are often the first-line therapy for metastatic liver disease, a majority of patients present with bilobar disease not amenable to curative local resection. Furthermore, by the time metastasis to the liver has developed, many tumors demonstrate a degree of resistance to systemic chemotherapy. Fortunately, catheter-directed and percutaneous locoregional approaches have evolved as major treatment modalities for unresectable metastatic disease. These novel techniques can be used for diverse applications ranging from curative intent for small localized tumors, downstaging of large tumors for resection, or locoregional control and palliation of advanced disease. Their use has been associated with increased tumor response, increased disease-free and overall survival, and decreased morbidity and mortality in a broad range of metastatic disease. This review explores recent advances in liver-directed therapies for metastatic liver disease from primary colorectal, neuroendocrine, breast, and lung cancer, as well as uveal melanoma, cholangiocarcinoma, and sarcoma. Therapies discussed include bland transarterial embolization, chemoembolization, radioembolization, and ablative therapies, with a focus on current treatment approaches, outcomes of locoregional therapy, and future directions in each type of metastatic disease. Competing Interests: Conflict-of-interest statement: There are no conflict of interests associated with any of the authors of this manuscript. (©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu